Published in Nanotoxicology on May 18, 2011
Models for oral uptake of nanoparticles in consumer products. Toxicology (2011) 1.07
Dissolution testing of hardly soluble materials by surface sensitive techniques: clotrimazole from an insoluble matrix. Pharm Res (2014) 1.00
Particular film formation of phenytoin at silica surfaces. Mol Pharm (2014) 0.94
Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties. Int J Nanomedicine (2012) 0.83
Nano-sized and micro-sized polystyrene particles affect phagocyte function. Cell Biol Toxicol (2013) 0.82
Crystallographic textures and morphologies of solution cast Ibuprofen composite films at solid surfaces. Mol Pharm (2014) 0.80
Nanoparticles modulate surfactant protein A and D mediated protection against influenza A infection in vitro. Philos Trans R Soc Lond B Biol Sci (2015) 0.77
Intracellular calcium levels as screening tool for nanoparticle toxicity. J Appl Toxicol (2015) 0.76
Nano-TiO2 penetration of oral mucosa: in vitro analysis using 3D organotypic human buccal mucosa models. J Oral Pathol Med (2016) 0.75
A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell (2009) 3.63
GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 3.38
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet (2011) 2.71
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. Cell (2005) 2.52
Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci (2002) 2.24
Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest (2013) 2.23
Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet (2009) 2.22
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
An ancient genome duplication contributed to the abundance of metabolic genes in the moss Physcomitrella patens. BMC Evol Biol (2007) 2.17
Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain (2011) 2.15
A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci U S A (2002) 2.11
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat Methods (2005) 1.93
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
A practical note on the use of cytotoxicity assays. Int J Pharm (2004) 1.63
A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci (2007) 1.49
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
Mouse phenotyping. Methods (2010) 1.43
Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. Am J Hum Genet (2010) 1.42
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41
Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol Psychiatry (2010) 1.39
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase. J Biol Chem (2010) 1.29
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Neuronal 3',3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci (2009) 1.28
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25
Cholesteryl ester hydrolase activity is abolished in HSL-/- macrophages but unchanged in macrophages lacking KIAA1363. J Lipid Res (2010) 1.20
A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci (2003) 1.17
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2007) 1.15
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine (2008) 1.15
Cytotoxicity of nanoparticles independent from oxidative stress. J Toxicol Sci (2009) 1.13
Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet (2005) 1.13
The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J (2009) 1.12
The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J Neurosci (2002) 1.12
The role of nanoparticle size in hemocompatibility. Toxicology (2009) 1.10
Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci (2009) 1.09
CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol (2010) 1.09
Innovations in phenotyping of mouse models in the German Mouse Clinic. Mamm Genome (2012) 1.09
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis (2010) 1.07
An integrated genome research network for studying the genetics of alcohol addiction. Addict Biol (2010) 1.07
Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci (2002) 1.05
Requirement of the RNA-editing enzyme ADAR2 for normal physiology in mice. J Biol Chem (2011) 1.05
Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci (2008) 1.05
Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther (2003) 1.05
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion. Eur J Pharm Biopharm (2011) 1.03
Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev (2010) 1.02
N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology (2011) 1.02
Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology (2005) 1.02
The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci U S A (2011) 1.02
Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm (2004) 1.02
Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology (2008) 1.02
Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci (2005) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
Analysis of the mouse transcriptome for genes involved in the function of the nervous system. Genome Res (2003) 1.00
SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One (2013) 1.00
Dissolution testing of hardly soluble materials by surface sensitive techniques: clotrimazole from an insoluble matrix. Pharm Res (2014) 1.00
An antinociceptive role for substance P in acid-induced chronic muscle pain. Proc Natl Acad Sci U S A (2011) 0.99
Cytotoxity of nanoparticles is influenced by size, proliferation and embryonic origin of the cells used for testing. Nanotoxicology (2011) 0.99
Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver Int (2011) 0.98
Incongruent pattern of neurokinin B expression in rat and mouse brains. Cell Tissue Res (2005) 0.97
CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc Natl Acad Sci U S A (2012) 0.97
Modulation of alcohol and nicotine responses through the endogenous opioid system. Prog Neurobiol (2009) 0.97
Analysis of the cellular expression pattern of beta-CGRP in alpha-CGRP-deficient mice. J Comp Neurol (2004) 0.96
The opioid peptides enkephalin and beta-endorphin in alcohol dependence. Biol Psychiatry (2008) 0.95
The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum (2009) 0.95
High mobility group N proteins modulate the fidelity of the cellular transcriptional profile in a tissue- and variant-specific manner. J Biol Chem (2013) 0.95
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol (2012) 0.94
An fMRI study on the acute effects of exercise on pain processing in trained athletes. Pain (2012) 0.94
Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci (2012) 0.93
Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol (2010) 0.93
Comparison of two in vitro systems to assess cellular effects of nanoparticles-containing aerosols. Toxicol In Vitro (2012) 0.93
Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds. Psychopharmacology (Berl) (2004) 0.92
Recombinant virus like particles as drug delivery system. Curr Pharm Biotechnol (2005) 0.92
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood (2007) 0.92
Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. PLoS One (2012) 0.92
Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int J Neuropsychopharmacol (2008) 0.92
Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol (2009) 0.92
EP4 receptor stimulation down-regulates human eosinophil function. Cell Mol Life Sci (2011) 0.92
Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release (2006) 0.92
Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6. Eur Neuropsychopharmacol (2009) 0.90
Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med (2009) 0.90
Peroxisomes in human and mouse testis: differential expression of peroxisomal proteins in germ cells and distinct somatic cell types of the testis. Biol Reprod (2007) 0.90
Anandamide effects on 5-HT(3) receptors in vivo. Eur J Pharmacol (2008) 0.90
Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol (2011) 0.89
Microphthalmia, parkinsonism, and enhanced nociception in Pitx3 ( 416insG ) mice. Mamm Genome (2009) 0.89
Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. Neuropharmacology (2009) 0.89
Action of polystyrene nanoparticles of different sizes on lysosomal function and integrity. Part Fibre Toxicol (2012) 0.88
Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur J Pharm Biopharm (2005) 0.88
Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release (2005) 0.87
Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm (2013) 0.87